Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of M
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
08:12am, Tuesday, 21'st Oct 2025
Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: G MAB ) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“ Pur
Why Is Genmab Stock Trading Lower On Monday?
11:57am, Monday, 20'th Oct 2025
On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endom
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 demonstrated 50% confirmed objective respons
GMAB or TECH: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 14'th Oct 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
06:23am, Tuesday, 14'th Oct 2025
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
10:51am, Monday, 06'th Oct 2025
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Why Genmab Stock Popped on Friday
05:29pm, Friday, 03'rd Oct 2025
Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bu
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 03'rd Oct 2025
Does Genmab A/S Sponsored ADR (GMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stock to Buy for October 3rd
11:01am, Friday, 03'rd Oct 2025
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
New Strong Buy Stocks for October 3rd
03:51am, Friday, 03'rd Oct 2025
DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of M
Why Genmab Stock Was Marching Higher Today
03:43pm, Tuesday, 30'th Sep 2025
One day after announcing a sizable acquisition, Denmark-based biotech Genmab (GMAB 4.67%) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the comp
Genmab A/S (GMAB) M&A Call Transcript
05:47pm, Monday, 29'th Sep 2025
Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
10:15am, Monday, 29'th Sep 2025
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re
